---
trial_id: 316
discovery_date: 2022-04-02 17:30:16.025699
date: 2022-04-02 17:30:16.025699
title: "A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300..."
summary: |
  <p>EudraCT Number: 2005-005985-35<br />Sponsor Protocol Number: 1206.15<br />Sponsor Name: Boehringer Ingelheim<br />Start Date: 2006-08-29<br />Medical condition: Relapsing forms of Multiple Sclerosis<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005985-35/NL">NL</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005985-35/CZ">CZ</a> (Prematurely Ended)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005985-35'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2005-005985-35<br />Sponsor Protocol Number: 1206.15<br />Sponsor Name: Boehringer Ingelheim<br />Start Date: 2006-08-29<br />Medical condition: Relapsing forms of Multiple Sclerosis<br />Disease: <br />Version: 8.1<br />SOC Term: <br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005985-35/NL">NL</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-005985-35/CZ">CZ</a> (Prematurely Ended)</p>